MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents
Journal Article: Journal of Clinical OncologyYear Published: (2015) Volume Number: 33, Article Number: TPS11111